China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Xiangzhong Pharmaceutical received marketing approval from the National Medical Products Administration for its brexpiprazole active pharmaceutical ingredient.

The ingredient is used for schizophrenia in adults, according to a Tuesday filing with the Shanghai bourse.

Double-Crane's investment in the product reached 9.7 million yuan.